Company Profile

Syros is committed to developing new standards of care for the frontline treatment of patients with hematologic malignancies. Driven by the motivation to help patients with blood disorders that have largely eluded other targeted approaches, Syros is developing tamibarotene, an oral selective RARĪ± agonist in frontline patients with higher-risk myelodysplastic syndrome and acute myeloid leukemia with RARA gene overexpression.

Contact Information

Investor Relations
Syros Pharmaceuticals
Karen Hunady
Director of Corporate Communications & Investor Relations

Stern Investor Relations, Inc.
Hannah Deresiewicz

Company Contact
Syros Pharmaceuticals, Inc.
35 CambridgePark Drive
Cambridge, MA 02140